Acute Myeloid Leukemia (AML) Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Gamida Cell, GlycoMimetics, ImmunityBio, Bellicum, Arog Pharmaceuticals

The Acute Myeloid Leukemia Market has a promising outlook, with several emerging therapies in various stages of clinical development. The overall dynamics of the Acute Myeloid Leukemia market are anticipated to change in the coming years owing to the expected launch of targeted therapies. Some of the most prominent ones include Dociparstat Sodium (Chimerix), Uproleselan (GlycoMimetics Incorporated), Crenolanib besylate (Arog pharmaceuticals), JSP191 (Jasper therapeutics), and others.

DelveInsight's "Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Acute Myeloid Leukemia therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Myeloid Leukemia treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Acute Myeloid Leukemia: An Overview
Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. Acute Myeloid Leukemia can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other body parts.

The most prevalent form of leukemia in adults is Acute Myeloid Leukemia, which makes up around 80% of all cases. It is characterized by ineffective erythropoiesis, and bone marrow failure is caused by the clonal growth of immature "blast cells" in the peripheral blood and bone marrow. AML is the most common acute leukemia in adults and primarily affects older people, with a median age of diagnosis of ~67 years. The chromosomal anomalies that each patient possesses are often exclusive to them. The frequency of anomalies is greater as people age.

Treatment of most patients with AML typically consists of two chemotherapy phases: remission induction (often just called induction) and consolidation (postremission therapy). There has been a plethora of drugs approved for this aggressive cancer, since 2017. The US FDA has approved DAURISMO, XOSPATA, IDHIFA, VENCLEXTA, TIBSOVO, RYDAPT, VYXEOS, MYLOTARG, and a few others to treat persons with newly diagnosed and relapsed/refractory acute myeloid leukemia. Likewise, the European Medicines Agency (EMA) has approved DAURISMO, XOSPATA, VENCLEXTA, RYDAPT, VYXEOS, and MYLOTARG.

Acute Myeloid Leukemia Market Key Facts
• Acute Myeloid Leukemia is one of the most common types of leukemia in adults. Still, Acute Myeloid Leukemia is fairly rare overall, accounting for only about 1% of all cancers.
• According to Cancer Research UK, Acute Myeloid Leukemia incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2016-2018, on average, each year, more than 4 in 10 new cases (42%) were in people aged 75 and over. Age-specific incidence rates rise gradually from birth, rise steadily from around age 50-54, rise more steeply from age 60-64, and drop in the oldest age groups.
• According to Miyamoto & Minami (2019), the annual incidence of Acute Myeloid Leukemia in Japan is 5.6 per 100,000. The annual incidence of Acute Myeloid Leukemia has increased with population age, reaching up to 10-17 cases per 100,000 patients who are over 69 years old, compared to 0.6-6 instances per 100,000 patients in less than 70 years old. As a result, individuals with Acute Myeloid Leukemia tend to be older than 69 years old.
• According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of acute myeloid leukemia was 4.3 per 100,000 men and women per year in the United States. The death rate was 2.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2014-2018 cases and 2015-2019 deaths.

Acute Myeloid Leukemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Myeloid Leukemia therapies in the market. It also provides a detailed assessment of the Acute Myeloid Leukemia market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Acute Myeloid Leukemia drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Acute Myeloid Leukemia Market Will Grow by 2032:
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Myeloid Leukemia Epidemiology
The epidemiology section covers detailed insights into the historical, and current Acute Myeloid Leukemia patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Acute Myeloid Leukemia Epidemiology Segmented as -
• Total Incident Cases of Acute Myeloid Leukemia in the 7MM (2019-2032)
• Gender-specific Cases of Acute Myeloid Leukemia in the 7MM (2019-2032)
• Age-specific Cases of Acute Myeloid Leukemia in the 7MM (2019-2032)
• Mutation-specific Cases of Acute Myeloid Leukemia in the 7MM (2019-2032)

Get Key Insights Into the Evolving Acute Myeloid Leukemia Epidemiology Trends @
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Myeloid Leukemia market or expected to be launched during the study period. The analysis covers the market share by Acute Myeloid Leukemia drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Acute Myeloid Leukemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Myeloid Leukemia Therapeutics Assessment
Several unmet needs exist in Acute Myeloid Leukemia. For instance, more-effective, less-toxic treatments are urgently needed because many patients with Acute Myeloid Leukemia are not candidates for standard induction therapy. Acute Myeloid Leukemia is also characterized by high rates of relapsed/refractory disease. Other unmet needs center on the poor quality of life from disease- and therapy-related toxicities. With several unmet needs, the therapeutics space is quite active, with a robust pipeline of drugs in clinical development, which is likely to boost the market growth in the coming years.

Several major pharma and biotech companies are developing Acute Myeloid Leukaemia therapies. Currently, Gamida Cell is leading the therapeutics market with its Acute Myeloid Leukaemia drug candidates in the most advanced stage of clinical development.

The Leading Players in the Acute Myeloid Leukemia Therapeutics Market Include:
Abbvie, Actinium Pharmaceuticals, Agastiya Biotech, AGC Biologics S.p.A., Agios Pharmaceuticals, Allogene therapeutics, Aprea Therapeutics, Aptevo Therapeutics, Armaceutica, Arog Pharmaceuticals, Astellas Pharma, Astex Pharmaceuticals, Inc., AstraZeneca, Bellicum Pharmaceuticals, BerGenBio ASA, Bio-Path Holdings, Biosight Ltd., Bristol-Myers Squibb, Cardiff Oncology, Celgene, CellCentric Ltd., Chimerix, Clear Creek Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Curis, Inc., Daiichi Sankyo., DCPrime BV, Delta-Fly Pharma, Forma Therapeutics, GEMoaB Monoclonals, Gilead Sciences, GlycoMimetics, GlycoMimetics Incorporated, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Immune-Onc Therapeutics, Immunicum, ImmunityBio, ImmunoGen, Inc., Immunomedics, Inc., Incyte Corporation, Janssen Research & Development, LLC, Jasper Therapeutics, Jazz Pharmaceuticals, Kronos Bio, MacroGenics, MediGene, Molecular Partners, New Epsilon Innovation Limited, NexImmune Inc., Novartis, Oncoceutics, Orca Bio, PersonGen BioTherapeutics, Pfizer, Poseida Therapeutics, Precigen, Inc., Rafael Pharmaceuticals Inc., Sellas Life Sciences Group, Sumitomo Dainippon Pharma Co., Ltd., Syndax Pharmaceuticals, Synimmune GmbH, Syros Pharmaceuticals, Takeda Oncology, TC BioPharm, Teva Pharmaceutical Industries, Xencor, Inc., and others.

Acute Myeloid Leukaemia Emerging and Marketed Drugs Covered in the Report Include:
• Omidubicel: Gamida Cell
• Uproleselan: GlycoMimetics
• ALT 803: ImmunityBio
• BPX-501: Bellicum Pharmaceuticals
• Devimistat (CPI-613): Rafael Pharmaceuticals Inc.
• Crenolanib: Arog Pharmaceuticals
And Many More

Learn More About the Emerging Therapies & Key Companies in the Acute Myeloid Leukemia Therapeutics Market:
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Myeloid Leukemia Competitive Intelligence Analysis
4. Acute Myeloid Leukemia Market Overview at a Glance
5. Acute Myeloid Leukemia Background and Overview
6. Acute Myeloid Leukemia Patient Journey
7. Acute Myeloid Leukemia Epidemiology and Patient Population
8. Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Myeloid Leukemia Unmet Needs
10. Key Endpoints of Acute Myeloid Leukemia Treatment
11. Acute Myeloid Leukemia Marketed Products
12. Acute Myeloid Leukemia Emerging Therapies
13. Acute Myeloid Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Acute Myeloid Leukemia Market Outlook (7 major markets)
16. Acute Myeloid Leukemia Access and Reimbursement Overview
17. KOL Views on the Acute Myeloid Leukemia Market.
18. Acute Myeloid Leukemia Market Drivers
19. Acute Myeloid Leukemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Healthcare Consulting and Competitive Intelligence Services by DelveInsight
Discover DelveInsight's Comprehensive Market Research and Consulting Services: https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Schizophrenia Market
https://www.delveinsight.com/report-store/schizophrenia-market

Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market

US Healthcare Outlook Bulimia Nervosa Market
https://www.delveinsight.com/report-store/bulimia-nervosa-market

Hepatitis B Virus (HBV) Infection Market
https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market

Pancreatic Cancer Market
https://www.delveinsight.com/report-store/pancreatic-cancer-market

Hepatitis C Market
https://www.delveinsight.com/report-store/hepatitis-c-market

Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

Cytomegalovirus (CMV) Infections Market
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market-insight-epidemiology-and-market-forecast

Spinal Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-fusion-devices-market

Gastro Intestinal Bleeding Market
https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market

Giant-Cell Arteritis Market
https://www.delveinsight.com/report-store/giant-cell-arteritis-market

Traveler's Diarrhea Market
https://www.delveinsight.com/report-store/travelers-diarrhea-market

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market

Patent Foramen Ovale (PFO) Closure Devices Market
https://www.delveinsight.com/report-store/patent-foramen-ovale-closure-devices-market

Invasive Pneumococcal Disease Market
https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market

Echocardiography Devices Market
https://www.delveinsight.com/report-store/echocardiography-devices-market

Primary Immune Deficiency (PID) Market
https://www.delveinsight.com/report-store/primary-immune-deficiency-pid-market

Narcolepsy Market
https://www.delveinsight.com/report-store/narcolepsy-market

Periodontal Disease Market
https://www.delveinsight.com/report-store/periodontal-disease-market

Postoperative Nausea and Vomiting (PONV) Market
https://www.delveinsight.com/report-store/postoperative-nausea-and-vomiting-ponv-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Acute Lymphoblastic Leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market

Hemodynamic Monitoring Systems Market
https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market

Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market

Food Allergy Market
https://www.delveinsight.com/report-store/food-allergy-market-insights

Embolotherapy Market
https://www.delveinsight.com/report-store/embolotherapy-market

Psychosis Market
https://www.delveinsight.com/report-store/psychosis-market

Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market

Asthma Market
https://www.delveinsight.com/report-store/asthma-market

Spinal Non-Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-non-fusion-devices-market

Corneal Dystrophy Market
https://www.delveinsight.com/report-store/corneal-dystrophy-market

Myasthenia Gravis Market
https://www.delveinsight.com/report-store/myasthenia-gravis-market

Substance use disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market

Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market

Injectable Drug Delivery Devices Market
https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market

Atherectomy Devices Market
https://www.delveinsight.com/report-store/atherectomy-devices-market

Chemotherapy Induced Nausea and Vomiting Market
https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-market

Structural Heart Devices Market
https://www.delveinsight.com/report-store/structural-heart-devices-market-market

Diabetic Eye Disease Market
https://www.delveinsight.com/report-store/diabetic-eye-disease-market

Tissue Heart Valves Market
https://www.delveinsight.com/report-store/tissue-heart-valves-cardiovascular-prosthetic-devices-market

Cardiovascular Prosthetic Devices Market
https://www.delveinsight.com/report-store/tissue-heart-valves-cardiovascular-prosthetic-devices-market

Diabetic Macular Edema (DME) Market
https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market

End-Stage Renal Disease (ESRD) Market
https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Renal Insufficiency Market
https://www.delveinsight.com/report-store/renal-insufficiency-market

Diabetic Retinopathy Market
https://www.delveinsight.com/report-store/diabetic-retinopathy-market

Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market

Herpes Simplex Market
https://www.delveinsight.com/report-store/herpes-simplex-market

Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.